{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:30:25Z","timestamp":1780356625142,"version":"3.54.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.acvd.2025.02.012","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:43:10Z","timestamp":1744717390000},"page":"330-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of diabetes in patients hospitalized for acute cardiac events: Joint position paper from the French Society of Cardiology and the French-speaking Diabetes Society"],"prefix":"10.1016","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9544-5031","authenticated-orcid":false,"given":"Patrick","family":"Henry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Jacqueminet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Lemesle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9856-5859","authenticated-orcid":false,"given":"Gaetan","family":"Prevost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Boccara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Cosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0533-9682","authenticated-orcid":false,"given":"Etienne","family":"Puymirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0788-8092","authenticated-orcid":false,"given":"Denis","family":"Angoulvant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Roubille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Kownator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Valensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-9818","authenticated-orcid":false,"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Verg\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2025.02.012_bib0465","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12933-021-01233-6","article-title":"Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys","volume":"20","author":"Ferrannini","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0470","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/heartjnl-2012-301629","article-title":"Newly diagnosed glucose intolerance and prognosis after acute myocardial infarction: comparison of post-challenge versus fasting glucose concentrations","volume":"98","author":"Tamita","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2025.02.012_bib0475","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1161\/CIRCULATIONAHA.117.030798","article-title":"Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015","volume":"136","author":"Puymirat","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2025.02.012_bib0480","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12933-015-0283-3","article-title":"Long-term clinical outcome in patients with acute coronary syndrome and dysglycaemia","volume":"14","author":"Kuhl","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0485","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1475-2840-11-78","article-title":"The prognostic value of different glucose abnormalities in patients with acute myocardial infarction treated invasively","volume":"11","author":"Mazurek","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0490","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2025.02.012_bib0495","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jchf.2014.08.004","article-title":"Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure","volume":"3","author":"Dei Cas","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.acvd.2025.02.012_bib0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2840-2-1","article-title":"Influence of diabetes mellitus on heart failure risk and outcome","volume":"2","author":"Bauters","year":"2003","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0505","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.acvd.2012.01.008","article-title":"Consensus statement on the care of the hyperglycaemic\/diabetic patient during and in the immediate follow-up of acute coronary syndrome","volume":"105","author":"Verges","year":"2012","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2025.02.012_bib0510","doi-asserted-by":"crossref","first-page":"e000148","DOI":"10.1136\/openhrt-2014-000148","article-title":"A decade of changes in clinical characteristics and management of elderly patients with non-ST elevation myocardial infarction admitted in Italian cardiac care units","volume":"1","author":"De Luca","year":"2014","journal-title":"Open Heart"},{"key":"10.1016\/j.acvd.2025.02.012_bib0515","doi-asserted-by":"crossref","first-page":"100579","DOI":"10.1016\/j.cpcardiol.2020.100579","article-title":"Diabetes as a predictor of in-hospital and one-year outcomes after decompensated heart failure","volume":"46","author":"Fairman","year":"2021","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0520","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12933-020-01026-3","article-title":"Impact of diabetes mellitus on mortality in patients with acute heart failure: a prospective cohort study","volume":"19","author":"Kong","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0525","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.thromres.2016.05.002","article-title":"High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction","volume":"144","author":"Dillinger","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.acvd.2025.02.012_bib0530","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ehj.2004.01.010","article-title":"Impact of diabetes mellitus on long-term survival in patients with congestive heart failure","volume":"25","author":"De Groote","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.02.012_bib0535","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ejhf.679","article-title":"In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry","volume":"19","author":"Targher","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2025.02.012_bib0540","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2337\/dc22-1586","article-title":"Prognosis after first-ever myocardial infarction in type 1 diabetes is strongly affected by chronic kidney disease","volume":"46","author":"Smidtslund","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.acvd.2025.02.012_bib0545","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1479164114551746","article-title":"Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the glucose tolerance in patients with acute myocardial infarction cohort","volume":"12","author":"Ritsinger","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.acvd.2025.02.012_bib0550","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-019-0970-6","article-title":"Prognostic value of HbA1c for in-hospital and short-term mortality in patients with acute coronary syndrome: a systematic review and meta-analysis","volume":"18","author":"Pan","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0555","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/S0140-6736(09)60553-5","article-title":"Stress hyperglycaemia","volume":"373","author":"Dungan","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2025.02.012_bib0560","doi-asserted-by":"crossref","first-page":"e14713","DOI":"10.14814\/phy2.14713","article-title":"Stress hyperglycemia, cardiac glucotoxicity, and critically ill patient outcomes current clinical and pathophysiological evidence","volume":"9","author":"Scheen","year":"2021","journal-title":"Physiol Rep"},{"key":"10.1016\/j.acvd.2025.02.012_bib0565","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00392-018-1213-7","article-title":"Prognostic impact of baseline glucose levels in acute myocardial infarction complicated by cardiogenic shock-a substudy of the IABP-SHOCK II-trial [corrected]","volume":"107","author":"Abdin","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0570","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.110.985911","article-title":"Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention","volume":"124","author":"Timmer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2025.02.012_bib0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms25052973","article-title":"New insights into endothelial dysfunction in cardiometabolic diseases: potential mechanisms and clinical implications","volume":"25","author":"Gallo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.acvd.2025.02.012_bib0580","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa011300","article-title":"Intensive insulin therapy in critically ill patients","volume":"345","author":"van den Berghe","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.02.012_bib0585","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJMoa0810625","article-title":"Intensive versus conventional glucose control in critically ill patients","volume":"360","author":"Finfer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.02.012_bib0590","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(99)08415-9","article-title":"Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview","volume":"355","author":"Capes","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2025.02.012_bib0595","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/eurheartj\/ehi230","article-title":"Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events","volume":"26","author":"Svensson","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.02.012_bib0600","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/2048872613489304","article-title":"Hyperglycemia at admission and during hospital stay are independent risk factors for mortality in high risk cardiac patients admitted to an intensive cardiac care unit","volume":"2","author":"Lipton","year":"2013","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.acvd.2025.02.012_bib0605","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1136\/bmj.314.7093.1512","article-title":"Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group","volume":"314","author":"Malmberg","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.acvd.2025.02.012_bib0610","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.02.012_bib0615","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.amjcard.2007.08.034","article-title":"Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study)","volume":"101","author":"Pinto","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0620","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.amjcard.2009.04.055","article-title":"Comparison of blood glucose values on admission for acute myocardial infarction in patients with versus without diabetes mellitus","volume":"104","author":"Ishihara","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0625","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.diabet.2019.01.012","article-title":"Glycaemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarction","volume":"45","author":"Benalia","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.acvd.2025.02.012_bib0630","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.2337\/dc12-0925","article-title":"Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction","volume":"36","author":"Su","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.acvd.2025.02.012_bib0635","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12933-018-0761-5","article-title":"Glycemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome","volume":"17","author":"Takahashi","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0640","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2337\/dc18-2047","article-title":"Glycemic variability is a powerful independent predictive factor of midterm major adverse cardiac events in patients with diabetes with acute coronary syndrome","volume":"42","author":"Gerbaud","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.acvd.2025.02.012_bib0645","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10557-016-6679-9","article-title":"Insulin in acute coronary syndrome: a narrative review with contemporary perspectives","volume":"30","author":"Nam","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.acvd.2025.02.012_bib0650","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1345\/aph.1A300","article-title":"Glucose-insulin-potassium solution for acute myocardial infarction","volume":"36","author":"Janiger","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.acvd.2025.02.012_bib0655","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0735-1097(95)00126-K","article-title":"Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year","volume":"26","author":"Malmberg","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0660","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/eurheartj\/ehm518","article-title":"The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial","volume":"29","author":"Mellbin","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.02.012_bib0665","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2337\/dc11-0706","article-title":"Piloting a novel algorithm for glucose control in the coronary care unit: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) trial","volume":"35","author":"Nerenberg","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.acvd.2025.02.012_bib0670","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1161\/CIRCULATIONAHA.117.030924","article-title":"Effect of basal insulin glargine on first and recurrent episodes of heart failure hospitalization: the ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)","volume":"137","author":"Gerstein","year":"2018","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.acvd.2025.02.012_bib0675","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.amjcard.2019.10.025","article-title":"A review of cardiovascular outcomes trials of glucose-lowering therapies and their effects on heart failure outcomes","volume":"124","author":"Nassif","year":"2019","journal-title":"Am J Cardiol"},{"issue":"Suppl.","key":"10.1016\/j.acvd.2025.02.012_bib0680","first-page":"789","article-title":"A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results","volume":"19","author":"Meinert","year":"1970","journal-title":"Diabetes"},{"key":"10.1016\/j.acvd.2025.02.012_bib0685","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/dom.12456","article-title":"Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer","volume":"17","author":"Abdelmoneim","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.acvd.2025.02.012_bib0690","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","article-title":"Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial","volume":"5","author":"Vaccaro","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0695","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2025.02.012_bib0700","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2025.02.012_bib0705","first-page":"1527","article-title":"[Use of metformin in diabetic patients with cardiac disease: benefit-risk balance]","volume":"9","author":"Scheen","year":"2013","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.acvd.2025.02.012_bib0710","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1001\/jama.2014.3315","article-title":"Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial","volume":"311","author":"Lexis","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2025.02.012_bib0715","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/CIRCRESAHA.118.313341","article-title":"Effect of intracoronary metformin on myocardial infarct size in swine","volume":"123","author":"Techiryan","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.acvd.2025.02.012_bib0720","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12933-019-0972-4","article-title":"Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study","volume":"18","author":"Bromage","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0725","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00392-017-1140-z","article-title":"Two-year follow-up of 4 months metformin treatment vs placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT","volume":"106","author":"Hartman","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0730","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2337\/diacare.28.7.1680","article-title":"Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project","volume":"28","author":"Inzucchi","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.acvd.2025.02.012_bib0735","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/CRD.0b013e3181846c53","article-title":"Metformin use in decompensated heart failure","volume":"16","author":"Boyd","year":"2008","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.acvd.2025.02.012_bib0740","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/dom.13448","article-title":"Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure","volume":"20","author":"Weir","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.acvd.2025.02.012_bib0745","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Metformin use and mortality among patients with diabetes and atherothrombosis","volume":"170","author":"Roussel","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.acvd.2025.02.012_bib0750","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/dom.12764","article-title":"Metformin-associated risk of acute dialysis in patients with type 2 diabetes: a nationwide cohort study","volume":"18","author":"Carlson","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.acvd.2025.02.012_bib0755","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.02.012_bib0760","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2025.02.012_bib0765","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.02.012_bib0770","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/1755-5922.12075","article-title":"Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants","volume":"32","author":"Wu","year":"2014","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.acvd.2025.02.012_bib0775","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007649","article-title":"Early and chronic dipeptidyl-peptidase-iv inhibition and cardiovascular events in patients with type 2 diabetes mellitus after an acute coronary syndrome: a landmark analysis of the EXAMINE trial","volume":"7","author":"Sharma","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.acvd.2025.02.012_bib0780","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/1479164114533355","article-title":"The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: a report from the BEGAMI study","volume":"11","author":"Hage","year":"2014","journal-title":"Diab Vasc Dis Res"},{"issue":"Suppl. 1","key":"10.1016\/j.acvd.2025.02.012_bib0785","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.13162","article-title":"A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials","volume":"20","author":"Aroda","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.acvd.2025.02.012_bib0790","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.02.012_bib0795","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.02.012_bib0800","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2025.02.012_bib0805","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCINTERVENTIONS.110.960476","article-title":"A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans","volume":"4","author":"Read","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.acvd.2025.02.012_bib0810","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","article-title":"Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction","volume":"33","author":"Lonborg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.02.012_bib0815","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00395-021-00842-2","article-title":"Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI)","volume":"116","author":"Garcia Del Blanco","year":"2021","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0820","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ijcard.2016.06.283","article-title":"No benefit of additional treatment with exenatide in patients with an acute myocardial infarction","volume":"220","author":"Roos","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2025.02.012_bib0825","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1080\/07853890.2017.1306653","article-title":"Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials","volume":"49","author":"Huang","year":"2017","journal-title":"Ann Med"},{"key":"10.1016\/j.acvd.2025.02.012_bib0830","first-page":"100063","article-title":"Role of glucagon-like peptide-1 agonist in patients undergoing percutaneous coronary intervention or coronary artery bypass grafting: a meta-analysis","volume":"11","author":"Ogbu","year":"2021","journal-title":"Am Heart J Plus"},{"key":"10.1016\/j.acvd.2025.02.012_bib0835","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1111\/dom.13847","article-title":"GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials","volume":"21","author":"Giugliano","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.acvd.2025.02.012_bib0840","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2025.02.012_bib0845","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2025.02.012_bib0850","doi-asserted-by":"crossref","first-page":"e078242","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.acvd.2025.02.012_bib0855","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.02.012_bib0860","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.02.012_bib0865","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.02.012_bib0870","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.02.012_bib0875","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.acvd.2025.02.012_bib0880","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.02.012_bib0885","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2025.02.012_bib0890","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2025.02.012_bib0895","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/ejhf.2149","article-title":"Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction","volume":"23","author":"Packer","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2025.02.012_bib0900","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.acvd.2025.02.012_bib0905","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.02.012_bib0910","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: the EMMY trial","volume":"43","author":"von Lewinski","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.02.012_bib0915","first-page":"664","article-title":"Prise de position de la Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD) sur les strat\u00e9gies d\u2019utilisation des traitements anti-hyperglyc\u00e9miants dans le diab\u00e8te de type 2-2023","volume":"17","author":"Darmon","year":"2023","journal-title":"Med Mal Metab"},{"key":"10.1016\/j.acvd.2025.02.012_bib0920","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213625002141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213625002141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T18:45:35Z","timestamp":1746729935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213625002141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1875213625002141"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2025.02.012","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of diabetes in patients hospitalized for acute cardiac events: Joint position paper from the French Society of Cardiology and the French-speaking Diabetes Society","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2025.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}